Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Incyte Corporation
National Cancer Institute (NCI)
Celgene
H. Lee Moffitt Cancer Center and Research Institute
ETOP IBCSG Partners Foundation
University of Kentucky
Pfizer
Bristol-Myers Squibb
Wake Forest University Health Sciences
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation
AbbVie